Scholarlink

Introduction <p>Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive behavior and lack of targeted therapies. Mitochondrial protease Lon Peptidase 1 (LONP1) has been associated with cancer progression; however, its clinical relevance and mechanistic role in triple-negative breast cancer (TNBC) remain unclear. This study investigates LONP1 as a potential prognostic biomarker and therapeutic target in breast cancer, with emphasis on TNBC.</p> Methods <p>We performed multi-omics analyses by integrating RNA-seq data from TCGA, GEO, and METABRIC cohorts. Functional studies were conducted using five breast cancer cell lines (BT-474, BT-549, MCF-7, MDA-MB-231 [TNBC], T-47D) with LONP1 knockdown or overexpression. Cell proliferation, migration, and invasion were assessed in vitro. In vivo tumorigenicity was evaluated in BALB/c nude mice. Mechanistic investigations included transcriptomic profiling and validation of IL-6 signaling using qPCR and Western blot.</p> Results <p>LONP1 was significantly overexpressed in TNBC versus non-TNBC tissues, correlating with advanced stage and poor survival. Functionally, LONP1 overexpression increased proliferation, migration, and invasion in models, while in vivo tumors exhibited accelerated growth. Transcriptomics revealed IL-6/JAK-STAT3 pathway activation, confirmed by upregulated IL-6 expression in LONP1-high cells.</p> Conclusion <p>LONP1 promotes TNBC progression through IL-6-mediated oncogenic signaling, indicating its potential as both a prognostic biomarker and a therapeutic target in aggressive breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lon peptidase 1 promotes proliferation and metastasis in breast cancer via interleukin 6 signaling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Yue Gao,
  • Chunyu Duan,
  • Sha Luan,
  • Xinyu Wang,
  • Peng Xu,
  • Yuying Jiao,
  • Peng Fu,
  • Changjiu Zhao

摘要

Introduction

Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive behavior and lack of targeted therapies. Mitochondrial protease Lon Peptidase 1 (LONP1) has been associated with cancer progression; however, its clinical relevance and mechanistic role in triple-negative breast cancer (TNBC) remain unclear. This study investigates LONP1 as a potential prognostic biomarker and therapeutic target in breast cancer, with emphasis on TNBC.

Methods

We performed multi-omics analyses by integrating RNA-seq data from TCGA, GEO, and METABRIC cohorts. Functional studies were conducted using five breast cancer cell lines (BT-474, BT-549, MCF-7, MDA-MB-231 [TNBC], T-47D) with LONP1 knockdown or overexpression. Cell proliferation, migration, and invasion were assessed in vitro. In vivo tumorigenicity was evaluated in BALB/c nude mice. Mechanistic investigations included transcriptomic profiling and validation of IL-6 signaling using qPCR and Western blot.

Results

LONP1 was significantly overexpressed in TNBC versus non-TNBC tissues, correlating with advanced stage and poor survival. Functionally, LONP1 overexpression increased proliferation, migration, and invasion in models, while in vivo tumors exhibited accelerated growth. Transcriptomics revealed IL-6/JAK-STAT3 pathway activation, confirmed by upregulated IL-6 expression in LONP1-high cells.

Conclusion

LONP1 promotes TNBC progression through IL-6-mediated oncogenic signaling, indicating its potential as both a prognostic biomarker and a therapeutic target in aggressive breast cancer.